2016
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis
Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo JJ, Lane HY, Sung FC, Liao CH, Arango C, Correll CU. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry 2016, 73: 247. PMID: 26792761, DOI: 10.1001/jamapsychiatry.2015.2923.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosT2DM riskHealthy controlsCoprimary outcomesT2DM incidencePsychiatric controlsIncidence rateType 2 diabetes mellitus riskMain modifiable risk factorsMultivariable meta-regression analysisSecond-generation antipsychotic prescriptionsCardiometabolic adverse effectsExposure-adjusted incidenceT2DM incidence rateModifiable risk factorsDiabetes mellitus riskStudy-level dataAntipsychotic-treated youthSystematic literature searchMeta-regression analysisOlanzapine prescriptionOlanzapine treatmentSecondary outcomesT2DM developmentAntipsychotic prescriptions
2012
ADHD medication use following FDA risk warnings.
Barry CL, Martin A, Busch SH. ADHD medication use following FDA risk warnings. The Journal Of Mental Health Policy And Economics 2012, 15: 119-25. PMID: 23001280, PMCID: PMC3896970.Peer-Reviewed Original Research
2008
Neuropsychiatric Disorders Associated With Streptococcal Infection: A Case-Control Study Among Privately Insured Children
Leslie DL, Kozma L, Martin A, Landeros A, Katsovich L, King RA, Leckman JF. Neuropsychiatric Disorders Associated With Streptococcal Infection: A Case-Control Study Among Privately Insured Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2008, 47: 1166-1172. PMID: 18724258, PMCID: PMC2783578, DOI: 10.1097/chi.0b013e3181825a3d.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttention Deficit Disorder with HyperactivityCase-Control StudiesChildChild, PreschoolCross-Sectional StudiesDepressive Disorder, MajorFemaleHealth SurveysHumansIncidenceInsurance, HealthMaleMigraine DisordersNeurocognitive DisordersObsessive-Compulsive DisorderOdds RatioOtitis MediaRiskSinusitisStreptococcal InfectionsTic DisordersTourette SyndromeUnited StatesConceptsMajor depressive disorderAttention-deficit/hyperactivity disorderPrior streptococcal infectionStreptococcal infectionObsessive-compulsive disorderTic disordersTourette syndromeNeuropsychiatric disordersConditional logistic regression modelsStreptococcal sore throatDiagnosis of OCDCase-control studyLogistic regression modelsSore throatIncident diagnosisEpidemiologic evidenceDepressive disorderSubsequent diagnosisNoninfectious conditionsScarlet feverChildren ages 4Immune systemInfectious diseasesInfectionDiagnosis
2006
Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study
Tierney E, Aman M, Stout D, Pappas K, Arnold LE, Vitiello B, Scahill L, McDougle C, McCracken J, Wheeler C, Martin A, Posey D, Shah B. Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology 2006, 191: 149-157. PMID: 17123125, DOI: 10.1007/s00213-006-0604-z.Peer-Reviewed Original ResearchConceptsClinical trialsClinical trial proceduresParent satisfactionDouble-blind clinical trialRandomized clinical trialsTrial proceduresResearch participationClinical responseAcute trialTreatment outcomesActive drugSimilar childrenStudy proceduresTrialsPharmacological researchAutistic disorderLearning TestPlaceboChildren's research participationEthnic minority subjectsChildrenRisperidoneWhite participantsGood allianceDrugsEffects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B. Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry 2006, 61: 545-550. PMID: 16730335, DOI: 10.1016/j.biopsych.2006.02.032.Peer-Reviewed Original ResearchConceptsRisperidone-induced increasesLong-term risperidone treatmentProlactin levelsRisperidone treatmentSerum prolactinOpen-label followWeeks of risperidoneBaseline prolactin levelsEffects of ShortPlacebo groupProlactin elevationReceptor polymorphismsWeek 8Baseline levelsMean increaseProlactinRisperidoneSerum samplesAdverse effectsPlaceboChildrenTreatmentMonthsDRD2 allelesAdolescentsPreface
Martin A, Bostic JQ. Preface. Child And Adolescent Psychiatric Clinics Of North America 2006, 15: xix-xxii. PMID: 16321721, DOI: 10.1016/j.chc.2005.09.001.Peer-Reviewed Original ResearchValidity of the Autism Diagnostic Interview-Revised
Lecavalier L, Aman MG, Scahill L, McDougle CJ, McCracken JT, Vitiello B, Tierney E, Arnold LE, Ghuman JK, Loftin RL, Cronin P, Koenig K, Posey DJ, Martin A, Hollway J, Lee LS, Kau AS. Validity of the Autism Diagnostic Interview-Revised. American Journal On Intellectual And Developmental Disabilities 2006, 111: 199-215. PMID: 16597187, DOI: 10.1352/0895-8017(2006)111[199:votadi]2.0.co;2.Peer-Reviewed Original Research
2005
Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman MG, Arnold M, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL. Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal Of Child And Adolescent Psychopharmacology 2005, 15: 869-884. PMID: 16379507, DOI: 10.1089/cap.2005.15.869.Peer-Reviewed Original ResearchConceptsSimpson-Angus Neurological Rating ScaleAbnormal Involuntary Movement ScaleAdverse eventsBody mass indexAcute trialTreatment-emergent adverse eventsTolerability of risperidoneCommon adverse eventsMost adverse eventsOpen-label extensionPlacebo-controlled trialMonths of treatmentUnanticipated adverse eventsSame adverse eventsLong-term safetyNeurological Rating ScaleOpen-label risperidoneRisperidone groupRisperidone therapyExtrapyramidal symptomsBlood assessmentMass indexPlacebo nonrespondersMovement ScaleLifetime diagnosis
2004
Age Effects on Antidepressant-Induced Manic Conversion
Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age Effects on Antidepressant-Induced Manic Conversion. JAMA Pediatrics 2004, 158: 773-780. PMID: 15289250, DOI: 10.1001/archpedi.158.8.773.Peer-Reviewed Original ResearchConceptsManic conversionAntidepressant classesPatient ageTime-dependent Cox proportional hazards modelsSelective serotonin reuptake inhibitorsCox proportional hazards modelNonbipolar mood disorderSerotonin reuptake inhibitorsProportional hazards modelRisk of conversionAdministrative national databaseEffect of agePharmacy claimsReuptake inhibitorsAntidepressant exposureDrug therapyTricyclic antidepressantsPeripubertal childrenAge effectsBipolar illnessMood disordersHigh riskMental health usersAntidepressant categoryHazards modelWeight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data
Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B. Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data. American Journal Of Psychiatry 2004, 161: 1125-1127. PMID: 15169706, DOI: 10.1176/appi.ajp.161.6.1125.Peer-Reviewed Original Research
2003
Trends in Psychotropic Medication Costs for Children and Adolescents, 1997-2000
Martin A, Leslie D. Trends in Psychotropic Medication Costs for Children and Adolescents, 1997-2000. JAMA Pediatrics 2003, 157: 997-1004. PMID: 14557161, DOI: 10.1001/archpedi.157.10.997.Peer-Reviewed Original ResearchConceptsCostly medicationsSelective serotonin reuptake inhibitorsPsychotropic medication costsPsychotropic medication utilizationSerotonin reuptake inhibitorsWarrants further studyMental health outpatientsMedication utilizationAtypical antidepressantsAtypical antipsychoticsPharmacy claimsReuptake inhibitorsMedication costsPsychotropic drugsDrug categoriesMedicationsNational databaseDrugsOverall useFurther studiesChildrenPrescription pricesAntipsychoticsAntidepressantsOutpatientsTwo-Year Trends in the Use of Seclusion and Restraint Among Psychiatrically Hospitalized Youths
Donovan A, Plant R, Peller A, Siegel L, Martin A. Two-Year Trends in the Use of Seclusion and Restraint Among Psychiatrically Hospitalized Youths. Psychiatric Services 2003, 54: 987-993. PMID: 12851435, DOI: 10.1176/appi.ps.54.7.987.Peer-Reviewed Original ResearchConceptsUse of seclusionProportion of episodesModalities of treatmentUse of medicationsTwo-year prevalenceState psychiatric hospitalIncidents of seclusionTwo-year trendsRestraint incidentsClinical dataEmergency basisPatient injuryPsychiatric hospitalCumulative durationPerformance improvement programEthnic minority groupsFurther studiesEpisodesChildrenShort episodesPercentConcurrent increaseSeclusionTotal numberMedicationsMultiple Psychotropic Pharmacotherapy Among Child and Adolescent Enrollees in Connecticut Medicaid Managed Care
Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L. Multiple Psychotropic Pharmacotherapy Among Child and Adolescent Enrollees in Connecticut Medicaid Managed Care. Psychiatric Services 2003, 54: 72-77. PMID: 12509670, DOI: 10.1176/appi.ps.54.1.72.Peer-Reviewed Original ResearchConceptsPsychotropic pharmacotherapyPeriod prevalenceCommunity-based clinical careMultivariate logistic regressionDrug class combinationsPsychotropic drug classesMedicaid Managed CarePharmacotherapy patternsYoung MedicaidMood stabilizersPrescription claimsPsychotropic medicationsCare databaseCare enrolleesDrug classesClinical careLow-income childrenAdolescent enrolleesPharmacotherapyPsychopharmacological carePharmacy informationOne-year periodLogistic regressionSociodemographic differencesStudy period
2002
Datapoints: Use of Multiple Psychotropic Drugs by Medicaid-Insured and Privately Insured Children
Martin A, Sherwin T, Stubbe D, Van Hoof T, Scahill L, Leslie D. Datapoints: Use of Multiple Psychotropic Drugs by Medicaid-Insured and Privately Insured Children. Psychiatric Services 2002, 53: 1508-1508. PMID: 12461205, DOI: 10.1176/appi.ps.53.12.1508.Peer-Reviewed Original ResearchEffects of Development on Olanzapine-Associated Adverse Events
WOODS SW, MARTIN A, SPECTOR SG, MCGLASHAN TH. Effects of Development on Olanzapine-Associated Adverse Events. Journal Of The American Academy Of Child & Adolescent Psychiatry 2002, 41: 1439-1446. PMID: 12447030, DOI: 10.1097/00004583-200212000-00015.Peer-Reviewed Original ResearchConceptsLiver function abnormalitiesAdverse eventsFunction abnormalitiesAtypical antipsychoticsComplaint riskWeight gainAtypical antipsychotic medicationsExtrapyramidal syndromeTardive dyskinesiaProlactin increaseAntipsychotic medicationAdolescent patientsRisk ratioPatient exposureSurveillance databaseAge groupsOlanzapineComplaintsConfidence intervalsExposure estimatesAntipsychoticsSedationPatientsChildrenAdultsRisperidone in Children with Autism and Serious Behavioral Problems
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal Of Medicine 2002, 347: 314-321. PMID: 12151468, DOI: 10.1056/nejmoa013171.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementAtypical antipsychotic agentsPlacebo groupSelf-injurious behaviorRisperidone groupAntipsychotic agentsAutistic disorderIrritability scoresDouble-blind trialPrimary outcome measureTreatment of adultsTraditional antipsychotic medicationsPercent decreaseSerious behavioral disturbancesAberrant Behavior ChecklistRisperidone therapyTardive dyskinesiaAntipsychotic medicationAverage weight gainOutcome measuresPositive responsePostsynaptic dopamineSerotonin receptorsBehavioral disturbancesSevere tantrums
2001
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill L, McCracken J, McDougle C, Aman M, Arnold L, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. Journal Of Child And Adolescent Psychopharmacology 2001, 11: 377-388. PMID: 11838820, DOI: 10.1089/104454601317261555.Peer-Reviewed Original ResearchConceptsPlacebo-controlled studyPlacebo-controlled discontinuation studyAutistic disorderSafety of risperidoneStudy of RisperidoneStandard pharmacological treatmentSelf-injurious behaviorDiscontinuation studyPharmacological treatmentClinical trialsInclusion criteriaLong-term effectsSevere tantrumsTrial designClinical relevanceClinical practiceLength of trialRisperidoneMultisite trialStudy designContinuous treatmentTrialsTreatment effectsDisordersMaintenance phase
2000
The use of psychotropic medications in young children: the facts, the controversy, and the practice.
Stubbe DE, Martin A. The use of psychotropic medications in young children: the facts, the controversy, and the practice. Connecticut Medicine 2000, 64: 329-33. PMID: 10909194.Peer-Reviewed Original Research
1999
Obsessive-Compulsive Symptoms in Prader-Willi and “Prader-Willi—Like” Patients
State M, Dykens E, Rosner B, Martin A, King B. Obsessive-Compulsive Symptoms in Prader-Willi and “Prader-Willi—Like” Patients. Journal Of The American Academy Of Child & Adolescent Psychiatry 1999, 38: 329-334. PMID: 10087695, DOI: 10.1097/00004583-199903000-00021.Peer-Reviewed Original ResearchConceptsPrader-Willi syndromeObsessive-compulsive symptomsManagement of BehavioralGroup of patientsMeasures of obesitySymptom-related impairmentOC symptomsGreater symptom severityFood-related problemsClinic patientsPrader-WilliPatientsSymptomsSymptom severityObesityDevelopmental delayGenetic abnormalitiesPWS groupMaladaptive behaviorsChromosome 15PWS genotypeSyndromeBehavioral phenotypesPWS critical regionProximal long arm